Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antivirals panel to discuss hepatitis C trials

Executive Summary

FDA's Antiviral Drugs Advisory Committee will meet Oct. 19-20 to discuss issues of clinical trial design pertaining to the development of chronic hepatitis C drugs, including the identification of appropriate control arms, study populations, endpoints and long-term follow-up. The meeting is being called "in response to the growing number of products in development for this indication." Novartis and Human Genome Sciences, Vertex Pharmaceuticals and Schering-Plough are currently developing hepatitis C therapies. The two-day meeting will be held at the Hilton in Silver Spring, Md., from 8 a.m. until 4 p.m. each day. [Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS047460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel